UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Blood-Brain Barrier Permeation and Efflux Exclusion of Anticholinergics Used in the Treatment of Overactive Bladder

Drugs & aging, 2012-04, Vol.29 (4), p.259-273

2012

Link zum Volltext

Verfügbarkeit prüfen

Extended-Release Trospium Chloride Improves Quality of Life in Overactive Bladder

Value in health, 2010-03, Vol.13 (2), p.251-257

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Oxybutynin Chloride Topical Gel for Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled, Multicenter Study

The Journal of urology, 2009-04, Vol.181 (4), p.1764-1772

2009

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder

Urology (Ridgewood, N.J.), 2010, Vol.75 (1), p.62-68

2010

Link zum Volltext

Verfügbarkeit prüfen

Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder

Expert opinion on pharmacotherapy, 2009-12, Vol.10 (18), p.3103-3111

2009

Link zum Volltext

Verfügbarkeit prüfen

Trospium 60 mg Once Daily (QD) for Overactive Bladder Syndrome: Results from a Placebo-Controlled Interventional Study

Urology (Ridgewood, N.J.), 2008-03, Vol.71 (3), p.449-454

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Tolterodine Extended Release and Dutasteride in Male Overactive Bladder Patients With Prostates >30 Grams

Urology (Ridgewood, N.J.), 2010-05, Vol.75 (5), p.1144-1148

2010

Link zum Volltext

Verfügbarkeit prüfen

Trospium chloride once‐daily extended release is efficacious and tolerated in elderly subjects (aged ≥75 years) with overactive bladder syndrome

BJU international, 2011-02, Vol.107 (4), p.612-620

2011

Link zum Volltext

Verfügbarkeit prüfen

Cognitive Effects of Oxybutynin Chloride Topical Gel in Older Healthy Subjects: A 1-Week, Randomized, Double-Blind, Placebo- and Active-Controlled Study

Clinical drug investigation, 2012-10, Vol.32 (10), p.707-714

2012

Link zum Volltext

Verfügbarkeit prüfen

Trospium Chloride: Distinct Among Other Anticholinergic Agents Available for the Treatment of Overactive Bladder

Urologic clinics of North America, 2006-11, Vol.33 (4), p.465-473

Staskin, David R.

2006

Link zum Volltext

Verfügbarkeit prüfen

The Effect of Elective Sham Dose Escalation on the Placebo Response During an Antimuscarinic Trial for Overactive Bladder Symptoms

The Journal of urology, 2012-05, Vol.187 (5), p.1721-1726

2012

Link zum Volltext

Verfügbarkeit prüfen

Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms

Neurourology and urodynamics, 2011-09, Vol.30 (7), p.1214-1219

2011

Link zum Volltext

Verfügbarkeit prüfen

Re: Giacomo Novara, Antonio Galfano, Silvia Secco, et al. A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder. Eur Urol 2008;54:740–64

European urology, 2009-05, Vol.55 (5), p.e84-e85

2009

Link zum Volltext

Verfügbarkeit prüfen

Re: Christopher R. Chapple, Vik Khullar, Zahava Gabriel, et al. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. Eur Urol 2008;54:543–62

European urology, 2009-03, Vol.55 (3), p.e49-e50

2009

Link zum Volltext

Verfügbarkeit prüfen

Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome

International Urogynecology Journal, 2009-12, Vol.20 (12), p.1431-1438

2009

Link zum Volltext

Verfügbarkeit prüfen

Considerations for the management of urgency symptoms in patients with overactive bladder syndrome

World journal of urology, 2009-12, Vol.27 (6), p.755-763

2009

Link zum Volltext

Verfügbarkeit prüfen

Oxybutynin topical and transdermal formulations: an update

Drugs of today (Barcelona, Spain : 1998), 2010-06, Vol.46 (6), p.417-425

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

European urology, 2020-01, Vol.77 (1), p.119-128

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

European urology, 2019-12, Vol.76 (6), p.767-779

2019

Link zum Volltext

Verfügbarkeit prüfen

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

International Urogynecology Journal, 2018-02, Vol.29 (2), p.273-283

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)

European urology, 2020-02, Vol.77 (2), p.211-220

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

ThemaUrinary Bladder, Overactive - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Female
(13)
Male
(13)
Urology & Nephrology
(13)
Double-Blind Method
(10)
Middle Aged
(10)
Muscarinic Antagonists - Therapeutic Use
(10)
Urology
(10)
Treatment Outcome
(9)
Aged
(8)
Benzilates
(7)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Muscarinic Antagonists - Adverse Effects
(7)
Nephrology. Urinary Tract Diseases
(7)
Urinary System Involvement In Other Diseases. Miscellaneous
(7)
Urinary Tract. Prostate Gland
(7)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Blood-Brain Barrier Permeation and Efflux Exclusion of Anticholinergics Used in the Treatment of Overactive Bladder

Extended-Release Trospium Chloride Improves Quality of Life in Overactive Bladder

Efficacy and Safety of Oxybutynin Chloride Topical Gel for Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled, Multicenter Study

Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder

Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder

Trospium 60 mg Once Daily (QD) for Overactive Bladder Syndrome: Results from a Placebo-Controlled Interventional Study

Efficacy and Safety of Tolterodine Extended Release and Dutasteride in Male Overactive Bladder Patients With Prostates >30 Grams

Trospium chloride once‐daily extended release is efficacious and tolerated in elderly subjects (aged ≥75 years) with overactive bladder syndrome

Cognitive Effects of Oxybutynin Chloride Topical Gel in Older Healthy Subjects: A 1-Week, Randomized, Double-Blind, Placebo- and Active-Controlled Study

Trospium Chloride: Distinct Among Other Anticholinergic Agents Available for the Treatment of Overactive Bladder

The Effect of Elective Sham Dose Escalation on the Placebo Response During an Antimuscarinic Trial for Overactive Bladder Symptoms

Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms

Re: Giacomo Novara, Antonio Galfano, Silvia Secco, et al. A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder. Eur Urol 2008;54:740–64

Re: Christopher R. Chapple, Vik Khullar, Zahava Gabriel, et al. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. Eur Urol 2008;54:543–62

Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome

Considerations for the management of urgency symptoms in patients with overactive bladder syndrome

Oxybutynin topical and transdermal formulations: an update

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)

Aktive Filter

Suchergebnisse filtern